(Q43007521)

12 November 2017

0 references

Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy? (English)

1 reference

12 November 2017

P A Vasey

1

1 reference

12 November 2017

S B Kaye

series ordinal

2

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

12 November 2017

1 reference

12 November 2017

76

1 reference

12 November 2017

11

1 reference

12 November 2017

1395-1397

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1997.568

12 November 2017

0 references

cites work

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Current perspectives on camptothecins in cancer treatment

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

A model for tumor cell killing by topoisomerase poisons.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

DNA intercalating anti-tumour agents

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

The S-phase cytotoxicity of camptothecin.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Effects of CPT-11 in combination with other anti-cancer agents in culture

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

Combined modalities of resistance in etoposide-resistant human KB cell lines.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228166

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

26 May 2018

1 reference

12 December 2020

Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons

1 reference

12 December 2020

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

12 December 2020

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors

1 reference

12 December 2020

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

1 reference

12 December 2020

Treatment of malignant melanoma with camptothecin (NSC-100880)

1 reference

12 December 2020

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

1 reference

12 December 2020

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1997.568

1 reference

Dimensions Publication ID

12 November 2017

1022029951

0 references

Fatcat ID

release_hjgcfnk5dzbw5avcxuqoadv5kq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hjgcfnk5dzbw5avcxuqoadv5kq

24 November 2022

mapped directly with Wikidata item

1 reference

12 November 2017

PubMed publication ID

9400932

1 reference